Centre National De La Recherche Scientifique

Universitè De Montpellier

Institut Curie

Abivax

Institut De Recherche Pour Le Developpement (ird)

Université De La Réunion Saint Denis

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique-cnrs

Inserm (institut National De La Sante Et De La Recherche Medicale)

University of Dundee

Université Montpellier 2 Sciences Et Techniques

Institut De Recherche Pour Le Developpement

Universite Montpellier 2

Societe Splicos

Inserm

Gilles Gadea

Pierre Roux

Jamal Tazi

Didier Scherrer

Romain Najman

Florence Mahuteau

Carsten Brock

Nathalie Cahuzac

Philippe Despres

Philippe Fort

Nikola Arsic

Véronique Gire

Aude Garcel

Julien Santo

Noelie Campos

Jean-Christophe Bourdon

Fanny Tomas

Michael Girardot

Wildriss Viranaicken

Patrick Mavingui

Fanny Thomas

Christelle Anguille

Kenneth Fernandes

Veronique Gire

Stephanie Vinot

Peggy Raynaud

Stéphanie Vinot

The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms expression; and also to screening methods for anti-cancer stem cells agents.

Delta133P53Beta and Delta133P53Gamma isoforms are biomarkers of cancer stem cells

A compound of formula (I): wherein A and A' independently represent a phenylene group or a pyridylene group; Ris a hydrogen atom or a (C-C)alkyl group; Ris a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; Ris a carbonyl group or a sulfonyl group; and Ris a &#x2014;NH&#x2014;(CH)&#x2014;NRRgroup or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, Rand Rrepresenting independently a (C-C)alkyl group, or Rand Rtogether with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

Compounds useful for treating cancer

The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of &#x394;133&#x3c1;536 isoform, &#x394;133&#x3c1;53&#x3b3; isoform, or both &#x394;133&#x3c1;536 and &#x394;133&#x3c1;53&#x3b3; isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in &#x394;133&#x3c1;536 isoform, &#x394;133&#x3c1;53&#x3b3; isoform, or both &#x394;133&#x3c1;536 and &#x394;133&#x3c1;53&#x3b3; isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing &#x394;133p536 isoform, &#x394;133&#x3c1;53&#x3b3; isoform, or both &#x394;133&#x3c1;536 and &#x394;133&#x3c1;53&#x3b3; isoforms expression; and also to screening methods for anti-cancer stem cells agents.

Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells

The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.

Vaccine compositions comprising an attenuated mutant Zika virus

The present invention relates to a compound of formula (I):  wherein A and A' independently represent a phenylene group or a pyridylene group; Ris a hydrogen atom or a (C-C)alkyl group; Ris a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; Ris a carbonyl group or a sulfonyl group; and Ris a &#x2014;NH&#x2014;(CH)&#x2014;NRRgroup or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, Rand Rrepresenting independently a (C-C)alkyl group, or Rand Rtogether with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.

Genomic sequences encoding for an attenuated mutant Zika virus

The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where:

Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging

The present invention relates to a compound of formula (I): wherein A and A' independently represent a phenylene group or a pyridylene group; Ris a hydrogen atom or a (C-C)alkyl group; Ris a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; Ris a carbonyl group or a sulfonyl group; and Ris a &#x2014;NH&#x2014;(CH)&#x2014;NRRgroup or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, Rand Rrepresenting independently a (C-C)alkyl group, or Rand Rtogether with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

A method of preventing, inhibiting, or treating cancer that includes contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: where:

Compounds for treating cancer

Growing community of inventors

Matelles, France

Gilles Gadea